Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

InVentive Europe

- PMLiVE

Daily Brief: AstraZeneca’s new San Fran home, Keytruda triumphs again, Novo branches out

A rapid round up from pharma, biotech and healthcare

AstraZeneca AZ

AstraZeneca expands alliance with Bicycle Therapeutics

Collaboration to seek out new respiratory and cardio-metabolic drugs

- PMLiVE

Better times ahead, promises AZ as Crestor drop outweighs new drugs

Patent expiry fading says Soriot, as oncology prospects look good

- PMLiVE

AstraZeneca and Emulate advance ‘organs-on-chips’ research partnership

Company advances partnership, aiming to integrate technology into full-scale R&D efforts

- PMLiVE

Daily brief:  Trump fails to ruffle PBMs, pharma, Jowell leaves brain tumour research legacy

A rapid round-up of recent happenings, plus some key events taking place this week

- PMLiVE

AZ’s Fasenra hit by COPD trial failure

Results give advantage to respiratory rivals GSK

AstraZeneca AZ

Maintenance OK boosts AstraZeneca’s Lynparza in Europe

New pill formulation also helps AZ and MSD against competitors in PARP class

- PMLiVE

Redx poaches AstraZeneca senior executive

Lisa Anson joins the UK biotech as its CEO

- PMLiVE

Publicis LifeBrands Team win UK young Cannes Lions competition

Tom Wordley and Jon Webb will represent the UK at the competition

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links